P

PharmaResearch Co Ltd
KOSDAQ:214450

Watchlist Manager
PharmaResearch Co Ltd
KOSDAQ:214450
Watchlist
Price: 329 500 KRW 0.3%
Market Cap: 3.5T KRW
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+46%
Revenue
Forecast
+12%
Operating Income
Forecast
+19%
Net Income
Forecast
+21%

Wall Street
Price Targets

Price Targets Summary
PharmaResearch Co Ltd

Wall Street analysts forecast PharmaResearch Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PharmaResearch Co Ltd is 339 514.29 KRW with a low forecast of 292 900 KRW and a high forecast of 409 500 KRW.

Lowest Forecast
Wall Street Target
292 900 KRW
11% Downside
Average Forecast
Wall Street Target
339 514.29 KRW
3% Upside
Highest Forecast
Wall Street Target
409 500 KRW
24% Upside
Lowest
Price Target
292 900 KRW
11% Downside
Average
Price Target
339 514.29 KRW
3% Upside
Highest
Price Target
409 500 KRW
24% Upside
PharmaResearch Co Ltd Competitors:
Price Targets
SKYE
Skye Bioscience Inc
702% Upside
ZYME
Zymeworks Inc
69% Upside
BMRN
Biomarin Pharmaceutical Inc
39% Upside
EXAS
Exact Sciences Corp
59% Upside
SKYE
Skye Bioscience Inc
702% Upside
ZYME
Zymeworks Inc
69% Upside
BMRN
Biomarin Pharmaceutical Inc
39% Upside
EXAS
Exact Sciences Corp
59% Upside
UTHR
United Therapeutics Corp
31% Upside
ASND
Ascendis Pharma A/S
29% Upside
SRZN
Surrozen Inc
211% Upside
OSE
OSE Immunotherapeutics SA
146% Upside

Revenue
Forecast

Revenue Estimate
PharmaResearch Co Ltd

For the last 8 years the compound annual growth rate for PharmaResearch Co Ltd's revenue is 27%. The projected CAGR for the next 4 years is 27%.

27%
Past Growth
27%
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
PharmaResearch Co Ltd

For the last 8 years the compound annual growth rate for PharmaResearch Co Ltd's operating income is 24%. The projected CAGR for the next 4 years is 36%.

24%
Past Growth
36%
Estimated Growth
Estimates Accuracy
-7%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
PharmaResearch Co Ltd

For the last 8 years the compound annual growth rate for PharmaResearch Co Ltd's net income is 25%. The projected CAGR for the next 4 years is 26%.

25%
Past Growth
26%
Estimated Growth
Estimates Accuracy
-19%
Average Miss
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PharmaResearch Co Ltd's stock price target?
Price Target
339 514.29 KRW

According to Wall Street analysts, the average 1-year price target for PharmaResearch Co Ltd is 339 514.29 KRW with a low forecast of 292 900 KRW and a high forecast of 409 500 KRW.

What is PharmaResearch Co Ltd's Revenue forecast?
Projected CAGR
27%

For the last 8 years the compound annual growth rate for PharmaResearch Co Ltd's revenue is 27%. The projected CAGR for the next 4 years is 27%.

What is PharmaResearch Co Ltd's Operating Income forecast?
Projected CAGR
36%

For the last 8 years the compound annual growth rate for PharmaResearch Co Ltd's operating income is 24%. The projected CAGR for the next 4 years is 36%.

What is PharmaResearch Co Ltd's Net Income forecast?
Projected CAGR
26%

For the last 8 years the compound annual growth rate for PharmaResearch Co Ltd's net income is 25%. The projected CAGR for the next 4 years is 26%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 239,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.